

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

ADDITIONAL RESUMPTION GUIDANCE

This announcement is made by Biosino Bio-Technology and Science Incorporation (the “**Company**”) pursuant to Rule 17.10 of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 31 March 2020, 13 May 2020, 17 June 2020, 31 August 2020 and 13 November 2020 (collectively, the “**Announcements**”) respectively in relation to, among other things, delay in publication of its annual results and annual report for the year ended 31 December 2019, delay in publication of its quarterly results and quarterly report for the three months ended 31 March 2020, delay in publication of its interim results and interim report for the six months ended 30 June 2020, delay in publication of its third quarterly results announcement and third quarterly report for the three months ended 30 September 2020, the resumption guidance, and the suspension of trading in the H shares of the Company on the Stock Exchange. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

ADDITIONAL RESUMPTION GUIDANCE

On 26 November 2020, the Company received a letter from the Stock Exchange setting out the following additional guidance (the “**Additional Resumption Guidance**”) for the resumption of trading in the shares of the Company in addition to the Resumption Guidance set out in the announcement of the Company dated 17 June 2020:

- to demonstrate that the Company maintains sufficient level of operations and assets in compliance with Rule 17.26 of the GEM Listing Rules.

The Stock Exchange may modify the Resumption Guidance and the Additional Resumption Guidance and/or issue further guidance as the Company’s circumstances change. Under Rule 9.14A of the GEM Listing Rules, the Stock Exchange may cancel the Company’s listing if trading in the Company’s shares has been suspended for 12 continuous months, expiring on 31 March 2021. If the Company fails to fulfil all the Resumption Guidance and fully comply with the GEM Listing Rules to the Stock Exchange’s satisfaction and resume trading in its shares by 31 March 2021, the Listing Department of the Stock Exchange will recommend the GEM Listing Committee to proceed with the cancellation of the Company’s listing. This is subject to the Stock Exchange’s right to impose a shorter specific remedial period under Rule 9.15 of the GEM Listing Rules if appropriate.

CONTINUED SUSPENSION OF TRADING IN H SHARES

Trading in the H shares of the Company has been suspended since 9:00 a.m. on 1 April 2020 and will continue to be suspended until further notice. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares or other securities of the Company.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Wu Lebin
Chairman and Executive Director

Beijing, the People’s Republic of China, 26 November 2020

As at the date of this announcement, the board (the “**Board**”) of directors of the Company (the “**Directors**”, each a “**Director**”) comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairman and non-executive Director

Dr. Sun Zhe (孫哲博士)

Vice chairman and executive Director

Mr. Chen Jintian (陳錦添先生)

Executive Directors

Mr. Chen Jianhua (陳建華先生)

Non-executive Directors

Ms. Cheng Yali (程亞利女士) and Mr. Wang Tao (王滔先生)

Independent non-executive Directors

Dr. Zheng Yongtang (鄭永唐博士), Mr. Ren Fujin (任孚今先生) and Ms. Li Li (李漓女士)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the “Latest Company Announcements” page for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.